STOCK TITAN

Scholar Rock Holding Corporation - SRRK STOCK NEWS

Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.

Scholar Rock Holding Corporation (SRRK) is a biotechnology company dedicated to pioneering a novel class of biologic therapies known as 'niche modulators'. These therapies selectively target the activation of growth factors within the disease microenvironment, offering a groundbreaking approach to treating serious medical conditions. Scholar Rock's initial proprietary and partnered drug discovery programs focus on specific growth factors, particularly members of the TGF-beta superfamily, which are critical in regulating cell growth and differentiation. These growth factors are notably present in the microenvironments of significant diseases like fibrosis, musculoskeletal disorders, and autoimmune diseases.

The company’s innovative therapeutic strategy stems from the foundational scientific discoveries of its founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School. These discoveries illuminate the molecular mechanisms of growth factor activation, empowering Scholar Rock to advance its ground-breaking treatments.

Scholar Rock is backed by a consortium of top-tier life sciences investors, including Polaris Partners and Arch Venture Partners. Its flagship product candidate, Apitegroma, is a selective, fully human, monoclonal antibody that inhibits the activation of the growth factor myostatin in skeletal muscle. This innovative mechanism holds promise for treating neuromuscular disorders. Another key product in the company's pipeline is SRK-181, which targets the activation of latent transforming growth factor beta-1 (TGFβ1) and is being developed to treat cancers that are resistant to existing anti-PD-(L)1 antibody therapies.

With its operations based in the United States, Scholar Rock continues to make significant strides in the biopharmaceutical industry, pushing the envelope of medical science and offering hope for effective treatments against some of the most challenging diseases.

Rhea-AI Summary
Scholar Rock (SRRK) reported significant progress in its Phase 3 SAPPHIRE trial for Spinal Muscular Atrophy (SMA) and received FDA clearance for a Phase 2 trial with apitegromab for obesity. The company ended 2023 with $280 million in cash, poised for a transformative year ahead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.77%
Tags
-
Rhea-AI Summary
Scholar Rock (SRRK) grants inducement equity awards totaling 201,469 shares to newly hired employees. The awards consist of stock options and restricted stock units under the 2022 Inducement Equity Plan. The options have exercise prices of $15.06 and $16.28, with vesting conditions tied to employee service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
management
-
Rhea-AI Summary
Scholar Rock (SRRK) announces its participation in upcoming investor conferences in March, including TD Cowen 44th Annual Health Care Conference, 3rd Annual Jefferies Biotech on the Bay Summit, and BMO Biopharma Spotlight Series: Obesity Day. The company aims to advance innovative treatments for spinal muscular atrophy (SMA) and other serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
conferences
Rhea-AI Summary
Scholar Rock (SRRK) grants inducement equity awards to new employees, totaling 131,688 shares of common stock, including stock options and restricted stock units. The awards are part of the 2022 Inducement Equity Plan, with options priced at $15.75 and vesting over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
management
-
Rhea-AI Summary
Scholar Rock (SRRK) appoints Katie Peng to Board of Directors and promotes Mo Qatanani to Chief Scientific Officer. Peng brings extensive commercial experience in neurology and rare diseases. Qatanani has a strong background in discovery and translational research. The company is preparing for the potential launch of apitegromab next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
management
-
Rhea-AI Summary
Scholar Rock (SRRK) presented preclinical findings at Keystone Symposia showing lean mass preservation, fat mass loss, and improved glucose metabolism with their novel myostatin inhibitor, SRK-439. The data suggests potential for SRK-439 to preserve lean mass and improve metabolic health in healthy weight loss management, with a proof-of-concept study planned for mid-2024. The company also announced FDA clearance for a Phase 2 trial of apitegromab to treat obesity, with trial initiation expected in mid-2024 and data in mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) announced preclinical data evaluating SRK-439, a selective myostatin inhibitor, for the treatment of cardiometabolic disorders. The data supports the potential of SRK-439 to preserve lean muscle mass during healthy weight loss. The company will present its findings at the Keystone Symposia’s Obesity: Causes and Consequences meeting in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) announced that the FDA has cleared the company’s Investigational New Drug application for its Phase 2 proof-of-concept trial of apitegromab to treat obesity in patients taking a GLP-1 receptor agonist. The study aims to evaluate the effect of apitegromab, a highly selective myostatin inhibitor, in preserving lean muscle mass as an adjunctive therapy in overweight and obese adults. The Phase 2 trial is set to initiate in mid-2024, with data expected in mid-2025. Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity and plans to file an IND for SRK-439 in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
-
Rhea-AI Summary
Scholar Rock (SRRK) announced the granting of inducement equity awards to a newly hired employee, covering 26,250 shares of its common stock. The awards consist of stock options and restricted stock units, subject to the terms of the company's 2022 Inducement Equity Plan. The options have an exercise price of $17.08 and will vest over time, with 25% vesting after the first year and the remaining 75% in quarterly installments. RSUs will vest in four equal annual installments, all subject to the employee's continued service at the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
management
Rhea-AI Summary
Scholar Rock (SRRK) provided corporate updates and highlighted upcoming priorities for 2024, including advancing their industry-leading antimyostatin pipeline to treat spinal muscular atrophy and cardiometabolic disorders. They reported year-end cash and cash equivalents of approximately $280 million and announced plans to present at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none

FAQ

What is the current stock price of Scholar Rock Holding Corporation (SRRK)?

The current stock price of Scholar Rock Holding Corporation (SRRK) is $44.78 as of December 20, 2024.

What is the market cap of Scholar Rock Holding Corporation (SRRK)?

The market cap of Scholar Rock Holding Corporation (SRRK) is approximately 4.1B.

What is Scholar Rock Holding Corporation's main focus?

Scholar Rock focuses on discovering and developing niche modulators that target growth factors in disease microenvironments for treating serious diseases.

What are niche modulators?

Niche modulators are biologic therapies that selectively target the activation of growth factors within the disease microenvironment.

Who founded Scholar Rock?

Scholar Rock was founded by Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School.

What is Apitegroma?

Apitegroma is a selective, fully human, monoclonal antibody developed by Scholar Rock to inhibit the activation of myostatin in skeletal muscle.

What diseases does Scholar Rock target?

Scholar Rock targets diseases such as neuromuscular disorders, cancer, fibrosis, and autoimmune diseases.

What is SRK-181?

SRK-181 is a product candidate that inhibits the activation of latent TGFβ1 and is being developed to treat cancers resistant to anti-PD-(L)1 therapies.

Who are some of Scholar Rock's investors?

Scholar Rock is backed by investors such as Polaris Partners and Arch Venture Partners.

Where is Scholar Rock based?

Scholar Rock operates in the United States.

What is the therapeutic approach of Scholar Rock?

The company's approach is based on targeting the activation of growth factors, specifically within the disease microenvironment, to treat serious conditions.

What recent achievements has Scholar Rock made?

Scholar Rock has advanced its product candidates, Apitegroma and SRK-181, showing promising therapeutic potential for treating serious diseases.

Scholar Rock Holding Corporation

Nasdaq:SRRK

SRRK Rankings

SRRK Stock Data

4.05B
91.72M
1.07%
98.55%
16.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE